Video

Dr. Infante on the Next Step in Melanoma Research

Author(s):

Jeffrey R. Infante, MD

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute on the next step in melanoma research.

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Alexander Spira, MD, PhD, FACP
September 18th 2024

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Adrian Sacher, MD, a thoracic oncologist and affiliate scientist of Princess Margaret Cancer-Centre of the University of Toronto in Toronto, Ontario, Canada
September 16th 2024

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors

Dirk Schadendorf, MD
September 15th 2024

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma